Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects...
Multiple MyelomaSubjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Study of ZIO-101 in Multiple Myeloma
Multiple MyelomaThe study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously...
Refractory Multiple MyelomaStage I Multiple Myeloma2 moreThis phase II trial studies the side effects and how well giving thalidomide, dexamethasone, and clarithromycin together works in treating patients with multiple myeloma previously treated with transplant. Biological therapies, such as thalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Dexamethasone also works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving thalidomide together with dexamethasone and clarithromycin after a transplant may be an effective treatment for multiple myeloma
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone...
Multiple MyelomaThe purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
Multiple MyelomaThe purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous transplantation.
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone...
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia9 moreThis phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant. Giving pentostatin and an infusion of the donor's T cells (donor lymphocyte infusion) after a donor stem cell transplant may stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before donor lymphocyte infusion may stop this from happening.
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV)...
Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast Cancer1 moreThe purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapsed Multiple Myeloma1 moreThe purpose if this study is to evaluate the side effects of the combination of bortezomib and Revlimid (CC-5013) in patients with relapsed and relapsed/refractory multiple myeloma.
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
Multiple MyelomaLymphocytic Leukemia3 moreThe purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
Multiple MyelomaPRIMARY STUDY OBJECTIVES To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.